Cell sensitivity to reaferon in patients with renal cell cancer after reaferon therapy.
Individual sensitivity of blood neutrophils to IFN-alpha2a was studied in vitro in patients with renal cell cancer before and after the first course of reaferon therapy. Cell sensitivity changed after reaferon therapy in 85% patients. This necessitates evaluation of individual cell sensitivity not only before therapy, but also before the next course of therapy.